Login / Signup

Intravenous methotrexate at a dose of 1 g/m2 incorporated into RCHOP prevented CNS relapse in high-risk DLBCL patients: A prospective, historic controlled study.

Wei WangYan ZhangLu ZhangChen YangJun FengHuacong CaiMiao ChenXinxin CaoJunling ZhuangTienan ZhuMinghui DuanWei ZhangJian LiDaobin Zhou
Published in: American journal of hematology (2020)
Keyphrases
  • end stage renal disease
  • high dose
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • diffuse large b cell lymphoma
  • low dose
  • patient reported outcomes